OIPE JC26
FEB 05 2004
PATENT & TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that the correspondence to which this certificate is affixed, including each document referred to therein as being enclosed or submitted therewith, is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

By: Lewis J. Kreisler Date: 2/4/04
Lewis J. Kreisler
Reg. No. 38522

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Shalini Sharma	Atty. Ref.:	18015-D5
Appl. No.:	10/684,730	Group Art Unit:	1624
Filed:	October 14, 2003	Examiner:	S. Patel
Conf. No.:	4306	Customer No.:	31976
Title:	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS		

* * * * * * * *

February 4, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Examiner is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are in the parent application serial number 10/167,839 and are therefore not being submitted with this IDS.

This Communication is being filed within three months of the filing date or before the mailing of a first Office Action on the merits. Consideration of this Statement is respectfully requested.

The documents WO 97/30017 and WO 98/07681, which are not in the English language each contain an English-language abstract. In addition, each of them contains chemical structures that use Latin characters and are not language specific.

It is believed that no fee is required in connection with the filing of this Statement. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,



Lewis J. Kreisler
Reg. No. 38522
Attorney for Applicant(s)

930 Clopper Road
Gaithersburg, MD 20878
Phone: (240) 631-2500 x3276
Facsimile: (240) 683-3794

OIPE JC29
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,845,231	07-04-1989	Kees	
		US- 5,948,803	09-07-1999	Maeda, et al.	
		US- 5817693 (abstract)			
		US- 4011321 (abstract)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 02/59077 (abstract)				
		WO 02/14291 (abstract)				
		WO 02/02119 (abstract)				
		WO 01/81340 (abstract)				
		BR 9802163 (abstract)				
		JP 01/181281 (abstract)				
		WO 00/23409 (abstract)				
		WO 99/62520 (abstract)				
		WO 98/25608 (abstract)				
		JP 10130241 (abstract)				

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC2
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] -Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 98/08836 (abstract)				
		WO 95/13262 (abstract)				
		WO 94/27993 (abstract)				
		WO 93/08799 (abstract)				
		JP 04159266 (abstract)				
		EP 407891 (abstract)				
		EP 393400 (abstract)				
		JP 01063570 (abstract)				
		WO 88/08418 (abstract)				
		EP 288190 (abstract)				

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] -Number[4]- Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		JP 61040270 (abstract)				
		JP 55015460 (abstract)				
		GB 1488330 (abstract)				
		JP 52025734 (abstract)				
		DE 2527066 (abstract)				
		DE 2459468 (abstract)				
		FR 2191887 (abstract)				
		JP 47025149 (abstract)				
		JP 56115747 (abstract)				
		DE 3012012 (abstract)				

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC36
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] -Number[4] - Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		JP 50014653 (abstract)				
		DE 2512673 (abstract)				
		DE 1929165 (abstract)				
		ZA 6705655 (abstract)				
		WO 97/30017	08-21-1997	Shinkai, et al.		
		WO 98/07681	02-26-1998	Moinet, et al.		
		WO 99/62520	12-09-1999	Young, et al.		
		EP 71399	02-09-1983	Tsung, et al.		
		WO 92/12123	07-23-1992	Schirlin, et al.		
		WO 00/63161	10-26-2000	Kolb, et al.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC26
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Group Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Karche, et al., "Electronic Effects in Migratory Groups...", Journal of Organic Chemistry, Vol. 66, No. 19, pages 6323-6332, 2001. (Abstract)	
		Poupardin, et al.,"First approach to the cycloisodityrosine unit of RA-IV", Tetrahedron Letters, Vol. 42, No. 8, pages 1523-1526, 2001. (Abstract)	
		Manthey, et al., "Synthesis of Human Ultraviolet Filter Compounds:...", Journal of Organic Chemistry, Vol. 64, No. 11, pages 3930-3933, 1999. (Abstract)	
		Wu, et al., "Improvement on the preparation of .beta.-keto esters", Huaxue Shiji, Vol. 20, No. 6, pages 376-377, 1998. (Abstract)	
		Wu, et al., "Total syntheses of furoguaiacin and related analogs", Huaxue Yanjiu Yu Yingyoung, Vol. 9, No. 6, pages 595-599, 1997. (Abstract)	
		Fadnavis, et al., "Baker's yeast mediated enantiospecific synthesis of anti-(2R,3R)...", Tetrahedron: Asymmetry, Vol. 8, No. 24, pages 4003-4006, 1997. (Abstract)	
		Wu, et al., "A modification of the Knorr oxidative coupling method for preparation of 1,4-diketones", Synthetic Communications, Vol. 27, No. 2, pages 331-336, 1997. (Abstract)	
		Girard, et al. "Syntheses of the syn and anti .alpha .-amino-.beta.-hydroxy acid of vancomycin:...", Tetrahedron Letters, Vol. 37, No. 44, pages 7967-7970, 1996. (Abstract)	
		Smith, et al., "Synthesis and PAF antagonist activity of some 2,5-diaryltetrahydrofurans incorporating PAF-like functional groups", European Journal of Medicinal Chemistry, Vol. 31, No. 5, pages 347-358, 1996. (Abstract)	
		Maruyama, et al., "A synthesis of (.+-.)-pinoresinol and its related compound using potassium persulfate (K2S208) oxidation of benzoylacetates", Heterocycles, Vol. 37, No. 2, pages 839-845, 1994. (Abstract)	
		Rao, et al., "Studies on cyclodepsipeptides. Part II. The total synthesis of jaspamide and geodiamolide-D", Tetrahedron Letters, Vol. 34, No. 44, pages 7085-7088, 1993. (Abstract)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC29
FEB 0 5 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Group Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		Colotta, et al., "Tricyclic heteroaromatic systems...", Farmaco, Vol. 46, No. 10, pages 1139-1154, 1991. (Abstract)	
		Dillard, et al., "(Phenylmethoxy) phenyl derivatives of w-oxo- and w-tetrazolylalkanoic acids...", J. Med. Chem., Vol. 34, No. 9, pages 2768-2778, 1991. (Abstract)	
		Bose, et al., "Synthesis of 4-phenylcoumarins from Dalbergia volubilis and Exostema caribaeum", Phytochemistry, Vol. 30, No. 7, pages 2438-2439, 1991. (Abstract)	
		Bose, et al., "Synthesis of 4-phenylcoumarins", Indian J. Chem., Sect. B, Vol. 29B, No. 5. pages 422-444, 1990. (Abstract)	
		Colotta, et al., "Tricyclic heteroaromatic systems...", J. Med. Chem., Vol. 33, No. 9, pages 2646-2651, 1990. (Abstract)	
		Kameo, et al., "Studies on hypolipidemic agents, IV. 3-[4-(Phenylthio) benzoyl] propionic acid derivatives", Chem. Pharm. Bull., Vol. 37, No. 5, pages 1260-1267, 1989. (Abstract)	
		Colotta, et al., "Tricyclic heteroaromatic systems: synthesis..." J. Pharm. Sci., Vol. 78, No. 3, pages 239-242, 1989. (Abstract)	
		Tanaka, et al., "Total synthesis of coumarinolignans, aquillochin (cleomiscosin C) and cleomiscosin D", Chem. Pharm. Bull., Vol. 36, No. 10, pages 3833-3837, 1988. (Abstract)	
		Parmar, et al., "Synthesis of new naturally occurring 4-phenyl-2H-1-benzopyran-2-ones", Bull. Chem. Soc. Jpn., Vol. 61, No. 6, pages 2277-2279, 1988. (Abstract)	
		Colotta, et al., "The correct synthesis of 2,3-dihydro-2-aryl-4-R-[1] benzopyrano [4,3-c] pyrazole-3-ones", Tetrahedron Letters, Vol. 28, No. 43, pages 5165-5168, 1987. (Abstract)	
		Tanaka, et al., "Total synthesis of daphneticin, a coumarinolignoid", Chem. Pharm. Bull., Vol. 34, No. 2 pages 628-632, 1986. (Abstract)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC26
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Group Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Ahluwalia, et al., "Synthesis of stevenin and melanettin", Symp. Pap.- IUPAC Int. Symp. Chem. Nat. Prod., 11th, Volume 3, pages 11-13, 1978. (Abstract)	
		Yamaguchi, "Degradation of protolignin with metallic sodium in liquid ammonia", Ringyo Shikenjó Kenkyu Hokoku, Vol 281, pages 1-78, 1976. (Abstract)	
		Okumura, et al., "Synthesis of chromone-3-carboxanilides", Chem. Pharm. Bull., Vol 22, No. 2, pages 331-336, 1974. (Abstract)	
		Von Wacek, et al., "Synthesis of methoxylated compounds for a comparative investigation of the stability of methyl ether groups", Monatsh. Chem, Vol. 97, No. 3, pages 744-753, 1966. (Abstract)	
		Iwasa, et al., "The preparation of the biosynthetic precursor 3,7-dihydroxy-2, 6-dimethoxyphenthroindolizidine", J. Nat. Prod., Vol. 51, No. 1, pages 172-175, 1998. (Abstract)	
		Wong, et al., "Wedelolactone and coumestan derivatives as new antihepatotoxic and antiphlogistic principles", Arzneim.-Forsch., Vol. 38, No. 5, pages 661-665, 1988. (Abstract)	
		Witiak, et al., "Synthetic aci-reductiones. 3,4-Dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a, 5,6,7,8,8a-hexahydro diastereomers", J. Med. Chem., Vol. 31, No. 7, pages 1437-1445, 1988. (Abstract)	
		Entzeroth, et al., "Preparation of 3- (3-indolyl) Lactic acids...", Liebigs Ann. Chem., No. 2, pages 226-230, 1983. (Abstract)	
		Bhakuni, et al., Biosynthesis of tylophorine and tylophorinine", Tetrahedron, Vol. 37, No. 2, pages 401-407, 1981. (Abstract)	
		Naidu, et al., "Debenzylation by nickel-aluminum alloy", J. Indian Inst. Sci., Vol. 62, No. 10, pages 177-180, 1980. (Abstract)	
		Oka, et al., "Syntheses of N-heterocyclic compounds. XXVI. Syntheses of pyrido [3,4-d] pyridazine derivatives", Chem. Pharm. Bull., Vol. 23, No. 10, pages 2306-2317, 1975. (Abstract)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC26
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Group Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Saunders, et al., "Syntheses of carbon-14-labeled prizidilol dihydrochloride", J. Labelled Compd. Radiopharm., Vol. 22, No. 9, pages 869-881, 1985. (Abstract)	
		Arnoldi, et al., "Synthesis and sweet taste of some 2-phenylbenzodioxanes", J. Agric. Food Chem., Vol. 34, No. 2, pages 339-344, 1986. (Abstract)	
		Winters, et al., "Synthesis and pregnancy terminating activity of pyrazolo [1,5-a] indoles and quinolines", Eur. J. Med. Chem.--Chim. Ther., Vol. 19, No. 3, pages 215-218, 1984. (Abstract)	
		Herbert, et al., "Biosynthesis of phenanthroindolizidine alkaloids: incorporation of 2-pyrrolidin-2-ylacetophenone and benzoylacetic acid and derivatives", J. Chem. Soc.,Perkin Trans.1, No. 4., pages 825-831, 1984. (Abstract)	
		Toja, et al., "Synthesis and pregnancy terminating activity of 2-arylpyrazolo [5,1-a] isoindoles and -isoquinolines", Eur. J. Med. Chem. -Chim. Ther., Vol. 17, No. 3, pages 223-227, 1982. (Abstract)	
		Ahluwalia, et al., "An unambiguous synthesis of melannein", Indian J. Chem., Sect. B, Vol. 21B, No. 3, pages 186-188, 1982. (Abstract)	
		Pelter, et al., "Synthesis and NMR spectra of 2,6- and 2,4-diaryl-3,7-dioxabicyclo [3.3.0] octanes", J. Chem. Soc., Perkin Trans. 1, No. 1, pages 183-190, 1982. (Abstract)	
		Mangla, et al., "Synthesis of substituted 6,7-diphenyl-1,2,3,5,8,8a-hexahydroindolizines", Indian J. Chem., Sect. B, Vol. 19B, No. 11, pages 931-937, 1980. (Abstract)	
		Mangla, et al. "Synthesis of tylophorine", Tetrahedron, Vol. 36, No. 17, pages 2489-2490, 1980. (Abstract)	
		Ahluwalia, et al., "A novel synthesis of 4-phenylcoumarins having a free hydroxyl group in the phenyl ring: synthesis of melanettin and stevenin", Heterocycles, Vol. 14, No. 9, pages 1329-1330, 1980. (Abstract)	
		Charlton, et al., "The synthesis of 2-methylchromone-3-carboxylic acid", J. Heterocycl. Chem., Vol. 17, No. 3, pages 593-594, 1980. (Abstract)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC26
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Group Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		Liu, et al., "The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes", Endocrinology, Vol 139, No. 11, pages 4531-4539, (1998).	
		Kees, et al., "Perfluoro-N-[4-(1 H-tetrazol-5-ylmethyl) Phenyl]-alkanamides. A New Class of Oral Antidiabetic Agents", Journal of Medicinal Chemistry, Vol. 32, pages 11-13, (1989).	
		Shinkai, et al. "4-(trans-4-Methylcyclohexyl)-4 Oxobutyric Acid (JTT-608). A New Class of Antidiabetic Agent", Journal of Medicinal Chemistry, Vol 41, No. 27, pages 5420-5428, (1998).	
		Abstract 560-P, Hodge, et al. "PN2022: Antidiabetic Efficacy and Reversal of Steatohepatitis in ob/ob Mice", Diabetes, Abstract Book 62nd Scientific Sessions, Vol. 51 Suppl. 2, page A139, June 2002.	
		Abstract 561-P, Hodge, et al., "PN2034: Orally Active Antidiabetic Agent with a Unique Spectrum of of Activity and Enhanced Safety Profile", Diabetes, Abstract Book 62nd Scientific Sessions, Vol. 51 Suppl. 2, page A139, June 2002.	
		Abstract 568-P, Lu, et al., "A Novel Antidiabetic Agent That Is a Selective PPAR Modulator", Diabetes, Abstract Book 62nd Scientific Sessions, Vol 51, Suppl. 2., page A141, June 2002.	
		Abstract 586-P, von Borstel, et al. "PN2034: Reversal of Insulin Resistance and Attenuation of Weight Gain in Mice on a High-Fat Diet", Diabetes, Abstract Book 62nd Scientific Sessions, Vol 51, Suppl. 2, page A145, June 2002.	
		Poster #560, Hodge, et al., "PN2022: Antidiabetic Efficacy and Reversal of Steatohepatitis in ob/ob Mice." Presentation at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on June 14- 18, 2002 and corresponding to Abstract 560-P.	
		Poster #561, Hodge, et al., "PN2034: Orally Active Antidiabetic Agent with a Unique Spectrum of Activity and Enhanced Safety Profile", Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on June 14-18, 2002 and corresponding to Abstract 560-P.	
		Poster #568, Lu, et al., "PN2034-A Novel Antidiabetic Agent That Is a Selective PPAR Modulator", Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on June 14-18, 2002 and corresponding to Abstract 568-P.	
		Poster #586, von Borstel, et al., "PN2034: Reversal of Insulin Resistance and Attenuation of Weight Gain in Mice on a High-Fat Diet", Presentation given at the 62nd Scientific Sessions, Meeting of the American Diabetes Association on June 14-18, 2002 and corresponding to Abstract 586-P.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC20
FEB 05 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 10

Complete if Known	
Application Number	10/684,730
Filing Date	October 14, 2003
First Named Inventor	Shalini Sharma
Group Art Unit	1624
Examiner Name	Sudhaker Patel
Attorney Docket Number	18015-D5

NON PATENT PUBLICATIONS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
		Owada, et al., "Improved synthesis of tricin", Nippon Kagaku Zasshi, Vol. 91, No. 10, pages 1002-1003, 1970. (Abstract).	
		Veronese, et al., "Ozonolysis of derivatices of 7-hydroxytryptophan", Gazz. Chim. Ital., Vol. 97, No. 1, pages 18-24, 1967. (Abstract)	
		Kawamatsu, et al., Studies on antihyperlipidemic agents. Part 1. Synthesis and hypolipidemic activities of phenoxyphenylalkanoic acid derivatives", Arzneim. Forsch, Vol. 30, Issue 3, pages 454-459, 1980. (Abstract)	
		Chemical Abstract DN 132:22755, also cited as WO99/62520.	
		Chemical Abstract DN 126:74645, also cited as J. Chem. Soc., Parkins Transactions 1, Org & Bio-Org. Chem., 21, 2603-2613, 1996.	
		Chemical Abstract DN 117:251790, also cited as Wo 92/12123.	
		Chemical Abstract DN 113: 115839, also cited as Synthetic communications, 20/5,773-81, 1990.	
		Chemical Abstract DN 99: 122287, also cited as EP 71399.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.